Flow-Diverting Devices versus Coil Embolization for Intracranial Aneurysms: A Systematic Literature Review and Meta-analysis

详细信息    查看全文

• 作者：Geng Zhou¹ ; Yue-Qi Zhu¹ ; Ming Su² ; Kai-Di Gao³ ; Ming-Hua Li¹ ; ^{liminghua12@163.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Cerebral aneurysm ; Coiling ; Endovascular ; Flow diverting device ; Stent
• 刊名：World Neurosurgery
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：88
• 期：Complete
• 页码：640-645
• 全文大小：2412 K

文摘

To review the literature on flow-diverting device (FDD) treatments for intracranial aneurysms (IAs) and to compare the safety and efficacy of FDDs with coil embolization treatment (CET) for IAs using a meta-analysis of published studies.

Methods

A systematic electronic search was conducted of PubMed, Springer Link, EBSCO, and the Cochrane Database on all accessible published articles through September 2015. Abstracts, full-text manuscripts, and the reference lists of retrieved articles were analyzed. Studies that explicitly compared FDD and CET approaches to the treatment of IAs were included. Odds ratios (ORs) and 95% CIs were calculated for the complete occlusion rate and the morbidity rate using a random-effects model.

Results

Nine studies were included in the analysis, containing retrospectively collected data for 863 patients. FDD treatment showed a significantly higher complete occlusion rate than CET (OR = 3.13; 95% confidence interval [CI], 2.11–4.65) and the subgroup of stent-assisted coiling did (OR = 2.08; 95% CI, 1.34–3.24). FDDs did not achieve a significantly lower overall morbidity rate compared with CET (OR = 0.87; 95% CI, 0.45–1.69) or the SAC (stent-assisted coiling) subgroup (OR = 0.86; 95% CI, 0.33–2.26), and our results did not show a significant difference in mortality between the two techniques.

Conclusions

FDD treatment of IAs yielded satisfactory results in complete occlusion rate compared with CET. The FDD procedure is feasible and has no significant difference in morbidity risk. Despite the findings reported herein, further validation with well-designed, multicenter randomized controlled trials is needed.